By prioritising community engagement, enabling remote enrollment, and clearly communicating risks and benefits, researchers and sponsors can help create safer, more inclusive clinical trials for pregnant individuals. Exp...
Press releases
-
ICON named Business & Finance Company of the Year and one of Forbes’ Best Employers for Diversity
ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide
-
ICON reports first quarter 2022 results
Quarter 1 adjusted revenue of $1.901.8 million representing a year on year increase of 121.6% or 125% on a constant currency basis.
-
ICON reports fourth quarter and full year 2021 results
Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.
-
ICON issues financial guidance for full year 2022
Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.
-
ICON named best contract research organisation in latest string of awards and recognitions
ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe
-
ICON releases environmental, social and governance report
ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.
-
ICON announces the expansion of its Accellacare Site Network
New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability
-
ICON reports third quarter 2021 financial results
Quarter 3 adjusted revenue of $1,870.4 million representing a year on year increase of 167% or 165% on a constant currency basis.
-
Tánaiste announces multi-million euro R&D support of ICON to accelerate decentralised clinical trial technology
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants.
-
ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
